Upadacitinib (Rinvoq®) is now being considered for coverage under the British Columbia Ministry of Health’s PharmaCare program. By filling out a questionnaire on a website called Your Voice, you can provide feedback about Rinvoq® for the treatment of giant cell arteritis.
You can give input if you are a B.C. resident and have giant cell arteritis, a caregiver to someone with giant cell arteritis, or if your group represents people who live with giant cell arteritis.
If you would like our help in providing your input, you can email your comments to feedback@jointhealth.org. Your feedback will be anonymized and collated with others who choose to provide it to ACE for submission on their behalf. Please provide your input to us by Friday, November 21, 2025 so that we may submit the questionnaire in time for the deadline.
The submission deadline is November 25, 2025. Patients and caregivers may give their input directly through the link below.
Please click on information sheet link below to learn more about Rinvoq® and the questionnaire link below to let BC PharmaCare hear Your Voice:
- To view the information sheet for Rinvoq® for the treatment of giant cell arteritis: click here
- To complete the Questionnaire as a patient, caregiver, or patient group representative: click here